Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amisulpride + mirtazapine is a combination of two pharmaceutical drugs used off-label, primarily in the management of psychotic depression and potentially other psychiatric conditions. Amisulpride is an atypical antipsychotic that acts as a selective dopamine D2 and D3 receptor antagonist, with preferential activity in the limbic system, leading to antipsychotic effects with relatively fewer extrapyramidal side effects. Mirtazapine is an antidepressant classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It works mainly by antagonizing central presynaptic alpha-2 adrenergic inhibitory autoreceptors and heteroreceptors, increasing norepinephrine and serotonin release; it also blocks serotonin 5-HT2 and 5-HT3 receptors as well as histamine H1 receptors, contributing to its sedative properties. The combination has been studied for efficacy in elderly patients with psychotic depression, showing potential benefit for both depressive and psychotic symptoms[1][4]. However, coadministration may increase the risk of QT interval prolongation and ventricular arrhythmias[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amisulpride + mirtazapine.